According to the research report titled ‘Global Haemophilia Market - Analysis by Type, By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) -? By Region (North America, Europe, APAC, ROW), By Country , available with Market Study Report, global haemophilia market is anticipated to register a CAGR of 6.84% over 2018-2024.
 

As per the report, factors including decrease in inhibitor formations in severe cases of Haemophilia, growing life expectancy of haemophiliac patients, and adoption of new treatments for the disease are key factors driving the market growth.  Moreover, increasing occurrence of the hemorrhages, dental and orthopedic surgeries, laceration, abrasion, and epistaxis are propelling the expansion of global haemophilia industry. Escalating healthcare expenditure and rising per capita income are also favoring the market outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1689406/
 

In terms of the type of ailment, global haemophilia market is split into Haemophilia A and Haemophilia B, of which, the former segment is anticipated to hold dominant position in the industry in the subsequent years. Elaborating on the treatment analysis, the industry is bifurcated into prophylaxis and on-demand segments.
 

Considering the regional landscape, global haemophilia market comprises of North America, Europe, Asia-Pacific, and rest of the word. Moving on to the country-level fragmentation, the industry is split into India, Japan, China, Brazil, United Kingdom, Germany, U.S., and Canada among others.
 

Based on the findings of the report, the largest regional share in the global haemophilia market, was represented by North America in the year 2018. On the other hand, the Asia-Pacific haemophilia market is expected to progress significantly by the year 2023. Vast customer base, predominantly in developing countries such as India and China are augmenting the regional demand. Additionally, the growing per capita spending on healthcare is likely to boost the haemophilia market growth in Asia-Pacific.
 

The majors companies operating in global haemophilia market are Alnylam Pharmaceuticals Inc., CSL Behring, Shire Plc, Dimension Therapeutics Inc., Catalyst Biosciences Inc., Aptevo Therapeutics Inc., Roche Holding AG, Pfizer Inc., Novo Nordisk A/S, and Bayer AG among others.